Alembic Pharmaceuticals receives US FDA nod for hypertension drugs
The approved drugs are generic versions of Daiichi Sankyo's Benicar and Benicar HCT tablets
 "Alembic Pharmaceuticals receives US FDA nod for hypertension drugs")
premium
The Vadodara-based Alembic Pharmaceuticals has received final approval from US Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs) for olmesartan medoxomil tablet (5 mg, 20 mg & 40 mg) and olmesartan medoxomil with hydrochlorothiazide tablet (20/12.5 mg, 40/12.5 mg and 40/25 mg).
The approved drugs are generic versions of Daiichi Sankyo's Benicar and Benicar tablets, which are indicated for the treatment of hypertension.
Benicar and Benicar HCT have an estimated market size of $ 1.8 billion for twelve months ending December 2016, according to IMS.
Alembic now has a total of 55 ANDA approvals (49 final approval and 6 tentative approvals) from the US FDA.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%